HomeComparePSBKF vs PFE

PSBKF vs PFE: Dividend Comparison 2026

PSBKF yields 4.71% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSBKF wins by $7.5K in total portfolio value
10 years
PSBKF
PSBKF
● Live price
4.71%
Share price
$0.67
Annual div
$0.03
5Y div CAGR
23.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.1K
Annual income
$9,483.50
Full PSBKF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PSBKF vs PFE

📍 PSBKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSBKFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSBKF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSBKF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSBKF
Annual income on $10K today (after 15% tax)
$400.51/yr
After 10yr DRIP, annual income (after tax)
$8,060.97/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $14,258.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSBKF + PFE for your $10,000?

PSBKF: 50%PFE: 50%
100% PFE50/50100% PSBKF
Portfolio after 10yr
$53.3K
Annual income
$17,871.11/yr
Blended yield
33.52%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PSBKF
No analyst data
Altman Z
0.1
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSBKF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSBKFPFE
Forward yield4.71%6.13%
Annual dividend / share$0.03$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.6%13.2%
Portfolio after 10y$57.1K$49.6K
Annual income after 10y$9,483.50$26,258.71
Total dividends collected$31.8K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSBKF vs PFE ($10,000, DRIP)

YearPSBKF PortfolioPSBKF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,282$582.39$9,153$693.39+$2.1KPSBKF
2$12,831$759.01$8,593$849.25+$4.2KPSBKF
3$14,726$997.12$8,336$1,066.78+$6.4KPSBKF
4$17,079$1,321.94$8,437$1,384.80+$8.6KPSBKF
5$20,046$1,771.00$9,013$1,875.40+$11.0KPSBKF
6$23,850$2,401.09$10,306$2,680.72+$13.5KPSBKF
7$28,820$3,299.96$12,820$4,101.38+$16.0KPSBKF
8$35,443$4,606.18$17,673$6,826.70+$17.8KPSBKF
9$44,468$6,543.66$27,543$12,591.86+$16.9KPSBKF
10$57,064$9,483.50$49,560$26,258.71+$7.5KPSBKF

PSBKF vs PFE: Complete Analysis 2026

PSBKFStock

Postal Savings Bank of China Co., Ltd., together with its subsidiaries, provides various banking products and services for retail and corporate customers in the People's Republic of China. Its Personal Banking segment offers savings products, such as demand, time, personal call, time/demand optional, and foreign currency deposits; passbooks; certificate of deposits; micro, personal pledged, and personal business loans; debit and credit cards; wealth management products and funds; and insurance agency services. This segment is also involved in distribution of fund products, electronic bonds, and precious metals; and provides payment and collection agency, various settlement, domestic remittance and exchange, cross-border remittance, personal exchange settlement and sale, and foreign currency exchange services. The company's Corporate Banking segment provides time, demand, call, and negotiated deposits; working capital, fixed asset, trade finance, stock pledge, land reserve, syndicated, real estate development, property mortgage, and consignment loans; cash management services; negotiable instruments; trade finance and international settlement services; and financial markets services. Its Treasury segment offers interbank lending transactions, repurchase and resale transactions, debt instrument investments, equity instrument investment, investment banking, bond securities, and wealth management products, etc., as well as trades in financial products comprising money market, fixed income, and foreign exchange products, as well as derivatives and precious metals. The company also provides online, mobile, and self-service banking services. As of December 31, 2021, it had 39,603 outlets, including 7,828 directly operated outlets and 31,775 agency outlets. The company was founded in 2007 and is headquartered in Beijing, the People's Republic of China. Postal Savings Bank of China Co., Ltd. is a subsidiary of China Post Group Corporation.

Full PSBKF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PSBKF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSBKF vs SCHDPSBKF vs JEPIPSBKF vs OPSBKF vs KOPSBKF vs MAINPSBKF vs JNJPSBKF vs MRKPSBKF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.